Anti-N-methyl-d-aspartate receptor encephalitis: A targeted review of clinical presentation, diagnosis, and approaches to psychopharmacologic management

Annals of Clinical Psychiatry

Volumn 26, Issue 1, 2014, Pages e1-e9

  Kruse, Jennifer L ^a,b   Jeffrey, Jessica K ^a   Davis, Michael C ^a,c   Dearlove, Joanna ^d   IsHak, Waguih William ^d   Brooks, John O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotic agents; Behavioral symptoms; Benzodiazepines; Limbic encephalitis; N methyl d aspartate receptor

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPHENHYDRAMINE; HALOPERIDOL; LORAZEPAM; METHYLPREDNISOLONE; NEUROLEPTIC AGENT; RITUXIMAB;

ADOLESCENT; AGITATION; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ANTICHOLINERGIC EFFECT; AUDITORY HALLUCINATION; CASE REPORT; CATATONIA; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSTONIA; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; INSOMNIA; MEDLINE; MENTAL DISEASE; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; PERSECUTORY DELUSION; PLASMAPHERESIS; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RESTLESSNESS; REVIEW;

EID: 84906732301     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Tunkel AR, Glaser CA, Bloch KC, et al. The manage-ment of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008;47:303-327.
2. Vincent A, Bien CG, Irani SR, et al. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 2011;10:759-772.
3. Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti- N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25-36.
4. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term out-come in patients with anti-NMDA receptor encepha-litis: an observational cohort study. Lancet Neurol. 2013;12:157-165.
5. Moghaddam B, Javitt D. From revolution to evolu-tion: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37:4-15.
6. Peery HE, Day GS, Dunn S, et al. Anti-NMDA recep-tor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev. 2012;11:863-872.
7. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63-74.
8. Gable MS, Sheriff H, Dalmau J, et al. The frequency of autoimmune N-methyl-d-aspartate receptor encepha-litis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2012;54:899-904.
9. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti- NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091-1098.
10. Mann A, Machado NM, Liu N, et al. A multidisci-plinary approach to the treatment of anti-NMDA-recep-tor antibody encephalitis: a case and review of the litera-ture. J Neuropsychiatry Clin Neurosci. 2012;24:247-254.
11. Florance-Ryan N, Dalmau J. Update on anti-N-methyl-d-aspartate receptor encephalitis in children and adolescents. Curr Opin Pediatr. 2010;22:739-744.
12. Dale RC, Irani SR, Brilot F, et al. N-methyl-d-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol. 2009;66:704-709.
13. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66:11-18.
14. Tanyi JL, Marsh EB, Dalmau J, et al. Reversible paraneoplastic encephalitis in three patients with ovar-ian neoplasms. Acta Obstet Gynecol Scand. 2012;91: 630-634.
15. Chapman MR, Vause HE. Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment. Am J Psychiatry. 2011;168:245-251.
16. Maggina P, Mavrikou M, Karagianni S, et al. Anti-N-methyl-d-aspartate receptor encephalitis presenting with acute psychosis in a preteenage girl: a case report. J Med Case Rep. 2012;6:224.
17. Francis A. Catatonia: diagnosis, classification, and treatment. Curr Psychiatry Rep. 2010;12:180-185.
18. Consoli A, Ronen K, An-Gourfinkel I, et al. Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report. Child Adolesc Psychiatry Ment Health. 2011;5:15.
19. Braakman HM, Moers-Hornikx VM, Arts BM, et al. Pearls & Oysters: electroconvulsive therapy in anti-NMDA receptor encephalitis. Neurology. 2010;75:e44-e46.
20. Watkins CJ, Pei Q, Newberry NR. Differential effects of electroconvulsive shock on the glutamate receptor mRNAs for NR2A, NR2B and mGluR5b. Brain Res Mol Brain Res. 1998;61:108-113.
21. Wilson JE, Shuster J, Fuchs C. Anti-NMDA recep-tor encephalitis in a 14-year-old female presenting as malignant catatonia: medical and psychiatric approach to treatment. Psychosomatics. 2013;54:585-589.
22. Barry H, Hardiman O, Healy DG, et al. Anti-NMDA receptor encephalitis: an important differential diagnosis in psychosis. Br J Psychiatry. 2011;199:508-509.
23. Sansing LH, Tüzün E, Ko MW, et al. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol. 2007;3:291-296.